Changjiang Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Changjiang Qin has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Lei Zhang
School of Basic Medical Sciences, Henan University, Kaifeng, China
2 shared publications - Meng Zheng
Henan Key Laboratory of Brain Targeted Bio-nanomedicine, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences, Henan University, Kaifeng, Henan 475004, China
2 shared publications Muhammad Ismail
Huaihe Hospital of Henan University, Henan University, Kaifeng, Henan, 475000, China; Henan Key Laboratory of Brain Targeted Bio-nanomedicine, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China
2 shared publicationsNingyang Wang
Henan Key Laboratory of Brain Targeted Bio-nanomedicine, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences, Henan University, Kaifeng, Henan, 475004, China
2 shared publications- Bingyang Shi
Henan-Macquarie Uni Joint Centre for Biomedical Innovation, Henan Key Laboratory of Brain Targeted Bio-nanomedicine, Henan International Joint Laboratory of Nanobiomedicine, School of Life Sciences, Henan University, Kaifeng, Henan 475004, China
1 shared publication - Bingyang Shi
School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, 2004, Australia
1 shared publication
Latest Publications
- Open Access
- 15 October 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 213
Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential
Chronic colitis is a major risk factor for colorectal cancer (CRC), particularly for colitis-associated colorectal cancer (CAC), where persistent inflammation drives the transition from mucosal injury to malignant transformation. Accumulating evidence indicates that gut microbiota dysbiosis, epithelial barrier disruption, microbial translocation, chronic immune activation, and aberrant inflammatory signaling collectively contribute to CAC initiation and progression. Sustained inflammation promotes oxidative stress, DNA damage, genetic/epigenetic alterations, and tumor microenvironment remodeling, ultimately facilitating tumor development and immune evasion. These processes form an interconnected pathogenic network linking microbial, inflammatory, genetic, immune, and stromal alterations. This review comprehensively summarizes the key drivers and molecular mechanisms of CAC, covering microbiota and barrier dysfunction, inflammatory signaling, oxidative stress and DNA damage, genetic and epigenetic alterations, and tumor microenvironment remodeling and immune dysregulation. We further review recent advances in diagnostic biomarkers, disease monitoring, chemoprevention, targeted therapies, and emerging interventions, including the potential utility of specific chemokine axes as biomarkers and therapeutic targets. Particular emphasis is placed on the translational challenges of linking mechanistic insights to diagnostic and therapeutic advances, including biomarker validation, stage-specific interventions, and patient stratification across disease progression. By integrating these interconnected mechanisms and therapeutic strategies, this review provides a comprehensive framework for understanding CAC pathogenesis and identifies opportunities for precision prevention, early detection, and multimodal treatment.
- 15 October 2026
- Published by Springer Nature in Molecular Biomedicine
- Vol. 7 (1) , 213
Open AccessColitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential
Chronic colitis is a major risk factor for colorectal cancer (CRC), particularly for colitis-associated colorectal cancer (CAC), where persistent inflammation drives the transition from mucosal injury to malignant transformation. Accumulating evidence indicates that gut microbiota dysbiosis, epithelial barrier disruption, microbial translocation, chronic immune activation, and aberrant inflammatory signaling collectively contribute to CAC initiation and progression. Sustained inflammation promotes oxidative stress, DNA damage, genetic/epigenetic alterations, and tumor microenvironment remodeling, ultimately facilitating tumor development and immune evasion. These processes form an interconnected pathogenic network linking microbial, inflammatory, genetic, immune, and stromal alterations. This review comprehensively summarizes the key drivers and molecular mechanisms of CAC, covering microbiota and barrier dysfunction, inflammatory signaling, oxidative stress and DNA damage, genetic and epigenetic alterations, and tumor microenvironment remodeling and immune dysregulation. We further review recent advances in diagnostic biomarkers, disease monitoring, chemoprevention, targeted therapies, and emerging interventions, including the potential utility of specific chemokine axes as biomarkers and therapeutic targets. Particular emphasis is placed on the translational challenges of linking mechanistic insights to diagnostic and therapeutic advances, including biomarker validation, stage-specific interventions, and patient stratification across disease progression. By integrating these interconnected mechanisms and therapeutic strategies, this review provides a comprehensive framework for understanding CAC pathogenesis and identifies opportunities for precision prevention, early detection, and multimodal treatment.
- 3 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124527
Polyphosphorylcholine-modified liposomes for glioblastoma-targeted siRNA delivery across the blood-brain barrier
- 3 August 2026
- Published by Elsevier in Biomaterials
- Vol. 337, 124527
Polyphosphorylcholine-modified liposomes for glioblastoma-targeted siRNA delivery across the blood-brain barrier
- Open Access
- 29 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Exploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials
Necroptosis, a non-apoptotic mode of programmed cell death, is characterized by the disintegration of the plasma membrane, ultimately leading to cell perforation and rupture. Recent studies have disclosed the mechanism of necroptosis and its intimate link with nanomaterials. Nanomedicine represents a novel approach in the development of therapeutic agents utilizing nanomaterials to treat a range of cancers with high efficacy. This article provides an overview of the primary mechanism behind necroptosis, the current research progress in nanomaterials, their potential use in various diseases—notably cancer, safety precautions, and prospects. The goal is to aid in the development of nanomaterials for cancer treatment.
- 29 April 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Open AccessExploring necroptosis: mechanistic analysis and antitumor potential of nanomaterials
Necroptosis, a non-apoptotic mode of programmed cell death, is characterized by the disintegration of the plasma membrane, ultimately leading to cell perforation and rupture. Recent studies have disclosed the mechanism of necroptosis and its intimate link with nanomaterials. Nanomedicine represents a novel approach in the development of therapeutic agents utilizing nanomaterials to treat a range of cancers with high efficacy. This article provides an overview of the primary mechanism behind necroptosis, the current research progress in nanomaterials, their potential use in various diseases—notably cancer, safety precautions, and prospects. The goal is to aid in the development of nanomaterials for cancer treatment.
- 28 January 2025
- Published by Elsevier in Biomaterials
- Vol. 318, 123138
Advanced nanoparticle engineering for precision therapeutics of brain diseases
- 28 January 2025
- Published by Elsevier in Biomaterials
- Vol. 318, 123138
Advanced nanoparticle engineering for precision therapeutics of brain diseases
- Open Access
- 31 July 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-7
Targeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer
Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibitor targeting PD-1/PD-L1 was only used to treat a small proportion of metastatic triple-negative breast cancer (TNBC), and the clinical outcomes was very limited. In addition, this regimen cannot prevent paclitaxel-induced peripheral neuropathy. Therefore, there was an urgent need for a novel target to enhance the antitumor activity of paclitaxel and alleviate chemotherapy-induced peripheral neuropathy in breast cancer. Here, we found that Dickkopf-1 (DKK1) expression was upregulated in multiply subtypes of human breast cancer specimens after paclitaxel-based chemotherapy. Mechanistic studies revealed that paclitaxel promoted DKK1 expression by inducing EGFR signaling in breast cancer cells, and the upregulation of DKK1 could hinder the therapeutic efficacy of paclitaxel by suppressing the infiltration and activity of CD8+ T cells in tumor microenvironment. Moreover, paclitaxel treatment in tumor-bearing mice also increased DKK1 expression through the activation of EGFR signaling in the primary sensory dorsal root ganglion (DRG) neurons, leading to the development of peripheral neuropathy, which is charactered by myelin damage in the sciatic nerve, neuropathic pain, and loss of cutaneous innervation in hindpaw skin. The addition of an anti-DKK1 antibody not only improved therapeutic efficacy of paclitaxel in two murine subtype models of breast cancer but also alleviated paclitaxel-induced peripheral neuropathy. Taken together, our findings providing a potential chemoimmunotherapy strategy with low neurotoxicity that can benefit multiple subtypes of breast cancer patients.
- 31 July 2024
- Published by Springer Nature in Molecular Cancer
- Vol. 23 (1) , 1-7
Open AccessTargeting DKK1 enhances the antitumor activity of paclitaxel and alleviates chemotherapy-induced peripheral neuropathy in breast cancer
Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibitor targeting PD-1/PD-L1 was only used to treat a small proportion of metastatic triple-negative breast cancer (TNBC), and the clinical outcomes was very limited. In addition, this regimen cannot prevent paclitaxel-induced peripheral neuropathy. Therefore, there was an urgent need for a novel target to enhance the antitumor activity of paclitaxel and alleviate chemotherapy-induced peripheral neuropathy in breast cancer. Here, we found that Dickkopf-1 (DKK1) expression was upregulated in multiply subtypes of human breast cancer specimens after paclitaxel-based chemotherapy. Mechanistic studies revealed that paclitaxel promoted DKK1 expression by inducing EGFR signaling in breast cancer cells, and the upregulation of DKK1 could hinder the therapeutic efficacy of paclitaxel by suppressing the infiltration and activity of CD8+ T cells in tumor microenvironment. Moreover, paclitaxel treatment in tumor-bearing mice also increased DKK1 expression through the activation of EGFR signaling in the primary sensory dorsal root ganglion (DRG) neurons, leading to the development of peripheral neuropathy, which is charactered by myelin damage in the sciatic nerve, neuropathic pain, and loss of cutaneous innervation in hindpaw skin. The addition of an anti-DKK1 antibody not only improved therapeutic efficacy of paclitaxel in two murine subtype models of breast cancer but also alleviated paclitaxel-induced peripheral neuropathy. Taken together, our findings providing a potential chemoimmunotherapy strategy with low neurotoxicity that can benefit multiple subtypes of breast cancer patients.
- Open Access
- 22 May 2019
- Published by Cell Physiol Biochem Press GmbH and Co KG in Cellular Physiology and Biochemistry
- Vol. 52 (6) , 1503-1516
ZNF281 Regulates Cell Proliferation, Migration and Invasion in Colorectal Cancer through Wnt/β-Catenin Signaling
Zinc Finger Protein 281 (ZNF281) was recently identified as a novel oncogene in several human carcinomas. However, the clinical significance of ZNF281 in colorectal cancer (CRC) and the molecular mechanisms by which ZNF281 promotes the growth and metastasis of CRC remain unknown. ZNF281 expression in CRC tissues was assessed, and the outcomes were analyzed to determine the clinical importance of ZNF281 expression. Cell Transwell assays and a wound healing assay were performed to assess the effects of ZNF281 on CRC cell migration and invasion in vitro. Western blotting was applied to analyze the potential mechanisms. ZNF281 mRNA and protein levels were significantly increased in CRC tissues compared with normal colon tissues, and high ZNF281 expression was associated with advanced T stage, N stage, TNM stage and differentiation. Therefore, ZNF281 expression might be an independent prognostic indicator in CRC patients. Moreover, knockdown of ZNF281 expression suppressed cell proliferation, migration and invasion by inhibiting the Wnt/β-catenin pathway. Our study indicates that ZNF281 plays a critical role in the progression and metastasis of CRC and could represent a potential therapeutic target for CRC.
- 22 May 2019
- Published by Cell Physiol Biochem Press GmbH and Co KG in Cellular Physiology and Biochemistry
- Vol. 52 (6) , 1503-1516
Open AccessZNF281 Regulates Cell Proliferation, Migration and Invasion in Colorectal Cancer through Wnt/β-Catenin Signaling
Zinc Finger Protein 281 (ZNF281) was recently identified as a novel oncogene in several human carcinomas. However, the clinical significance of ZNF281 in colorectal cancer (CRC) and the molecular mechanisms by which ZNF281 promotes the growth and metastasis of CRC remain unknown. ZNF281 expression in CRC tissues was assessed, and the outcomes were analyzed to determine the clinical importance of ZNF281 expression. Cell Transwell assays and a wound healing assay were performed to assess the effects of ZNF281 on CRC cell migration and invasion in vitro. Western blotting was applied to analyze the potential mechanisms. ZNF281 mRNA and protein levels were significantly increased in CRC tissues compared with normal colon tissues, and high ZNF281 expression was associated with advanced T stage, N stage, TNM stage and differentiation. Therefore, ZNF281 expression might be an independent prognostic indicator in CRC patients. Moreover, knockdown of ZNF281 expression suppressed cell proliferation, migration and invasion by inhibiting the Wnt/β-catenin pathway. Our study indicates that ZNF281 plays a critical role in the progression and metastasis of CRC and could represent a potential therapeutic target for CRC.